Price movement over the last 24 hours
Alcon AG vs VanEck Semiconductor ETF — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while VanEck Semiconductor ETF trades at $590.31. The key difference: Alcon AG pays a 0.54% dividend while VanEck Semiconductor ETF pays none, and VanEck Semiconductor ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | SMH | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | — |
52-Week High | $92.22 | $668.91 |
52-Week Low | $62.02 | $283.48 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SMH trades at $581.45, down 1.83% amid a semiconductor sector sell-off. Technical indicators show a neutral bias with mixed moving averages and oscillators, while support and resistance levels suggest consolidation near $609 pivot. Recent news highlights chip stock volatility, with JPMorgan advising to buy the dip despite hedge fund outflows. The ETF remains a high-beta play on AI-driven semiconductor demand, though financial ratios are unavailable for valuation context.
Outlook hinges on AI capex cycles and memory chip shortages, but risks include sector rotation and earnings pressure. Institutional sentiment is cautious despite long-term growth themes, with technicals indicating near-term range-bound action. Investors face volatility from hyperscaler shifts and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →